Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × perflutren × Clear all

Phase

Phase 1 8 Phase NA 6 Phase 2 6 Phase EARLY_PHASE1 4 Phase 3 3 Phase 4 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Anatomic Stage III Breast Cancer AJCC v8 1

Interventions

Cisplatin 97 Gemcitabine 64 Paclitaxel 61 Carboplatin 60 Docetaxel 59 Capecitabine 59 Fluorouracil 58 Oxaliplatin 56 Cyclophosphamide 54 Radiotherapy 50 Drug Therapy 46 Bevacizumab 37 pembrolizumab 36 Leucovorin 32 Magnetic Resonance Spectroscopy 31 Doxorubicin 31 Dexamethasone 31 Etoposide 26 Cytarabine 26 Pemetrexed 25 Nivolumab 24 Methotrexate 24 Radiation 20 Vincristine 18 apatinib 17 Rituximab 17 Prednisone 17 Letrozole 17 venetoclax 16 Trastuzumab 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04715958 2026-04-06

SHAPE Neoadjuvant Chemotherapy Response

Thomas Jefferson University

Phase 2/3 Recruiting

Anatomic Stage III Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon ⚡